Egyptian Price Reform Ruling Soon; What's Next For MNC Drug Makers?
This article was originally published in PharmAsia News
Executive Summary
In less than one month, the Supreme Administrative Court of Egypt will resume proceedings on Decree 373, the new drug pricing scheme proposed by the Ministry of Health to simplify the current system and make prices more predictable. The proposals have encountered balking from both drug makers and consumer advocacy groups, and now healthcare analysts think the reforms may need major reworking
You may also be interested in...
PhamAsia News Top Editors' Picks Of 2010
More outsourcing of clinical trials and manufacturing to Asia continued in 2010 as both U.S. and European pharma companies allocated more resources to emerging markets where growth is expected to remain in the double digits for the next five years. At the same time, more M&As and consolidation occurred in a frantic search for innovation that will likely continue. As patents begin to expire, readers can expect many Asian companies to grab the spotlight with biosimilar strategies increasingly coming out of Asia
PhamAsia News Top Editors' Picks Of 2010
More outsourcing of clinical trials and manufacturing to Asia continued in 2010 as both U.S. and European pharma companies allocated more resources to emerging markets where growth is expected to remain in the double digits for the next five years. At the same time, more M&As and consolidation occurred in a frantic search for innovation that will likely continue. As patents begin to expire, readers can expect many Asian companies to grab the spotlight with biosimilar strategies increasingly coming out of Asia
Egyptian Drug Price Reform: New Trade Barrier Or Demand Driver?
Egypt, an emerging pharmaceutical market, is implementing a series of healthcare and drug pricing reforms. The new drug pricing regime, a streamlined registration process and the government's initiative to widen health insurance coverage, could help drive up domestic demand for pharmaceutical products, especially for branded generics in the country